Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00447772 |
|
Recruitment Status :
Completed
First Posted : March 15, 2007
Results First Posted : July 30, 2018
Last Update Posted : November 22, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cervical Dystonia | Biological: Botulinum toxin type A | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 516 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Open Multicentre Study to Demonstrate the Efficacy and Safety of Botulinum Toxin A (500 Units Dysport®) in the Treatment of Heterogeneous Forms of Cervical Dystonia |
| Study Start Date : | October 2004 |
| Actual Primary Completion Date : | February 2008 |
| Actual Study Completion Date : | April 2008 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: 1 |
Biological: Botulinum toxin type A
Active Drug: Botulinum type A toxin (Dysport®) 500 Units / 2.5 ml injected in muscles involved in cervical dystonia
Other Name: AbobotulinumtoxinA (Dysport®) |
- Change From Baseline in the Total Score of the Tsui Rating Scale (Patient in Sitting Position) at the First On-treatment Visit (Week 4 or Week 12) [ Time Frame: Baseline to Week 4 or Week 12 (up to 12 weeks) ]
The Tsui rating scale measures severity and duration of head deviation, shoulder elevation and head tremor. This instrument is based on 4 subscores:
- Subscore A: amplitude of rotation, deflection (tilt) and ante- / retrocollis (range: 0-9 points)
- Subscore B: duration of movement (values 1 or 2)
- Subscore C: severity and duration of shoulder elevation (range: 0-3 points)
- Subscore D: severity and duration of tremor (range: 0-4 points).
The total score was calculated as follows: total score = subscores (A x B) + C + D. The total score ranges between 0 and 25 points. A high total score represents severe CD.
The mean change in the total score of the Tsui rating scale (patient in the sitting position) between baseline (Week 0 visit) and the first on-treatment visit (Week 4 or Week 12 visit) is presented.
- Change in the Total Score of the Tsui Rating Scale (Patient in Sitting Position) Between Visit 1 (Week 0) and Visit 3 (Week 12) [ Time Frame: Baseline to Week 12 ]
The Tsui rating scale measures severity and duration of head deviation, shoulder elevation and head tremor. This instrument is based on 4 subscores:
- Subscore A: amplitude of rotation, deflection (tilt) and ante- / retrocollis (range: 0-9 points)
- Subscore B: duration of movement (values 1 or 2)
- Subscore C: severity and duration of shoulder elevation (range: 0-3 points)
- Subscore D: severity and duration of tremor (range: 0-4 points).
The total score was calculated as follows: total score = subscores (A x B) + C + D. The total score ranges between 0 and 25 points. A high total score represents severe CD.
The mean change in the total score of the Tsui rating scale (patient in the sitting position) between baseline (Week 0 visit) and the Week 12 visit is presented.
- Change in the Total Score of the Tsui Rating Scale (Patient Walking) Between Baseline (Week 0) and Visit 2 (Week 4) and Visit 3 (Week 12) [ Time Frame: Baseline to Week 4 and Week 12 ]
The Tsui rating scale measures severity and duration of head deviation, shoulder elevation and head tremor. This instrument is based on 4 subscores:
- Subscore A: amplitude of rotation, deflection (tilt) and ante- / retrocollis (range: 0-9 points)
- Subscore B: duration of movement (values 1 or 2)
- Subscore C: severity and duration of shoulder elevation (range: 0-3 points)
- Subscore D: severity and duration of tremor (range: 0-4 points).
The total score was calculated as follows: total score = subscores (A x B) + C + D.
The total score ranges between 0 and 25 points. A high total score represents severe CD.
The mean changes in the total score of the Tsui rating scale (patient walking) between baseline (Week 0 visit) and the Week 4 and Week 12 visits are presented.
- Change in the 4 Subscores of the Tsui Rating Scale (Patient in the Sitting Position) Between Visit 1 (Week 0) and Visit 2 (Week 4) and Visit 3 (Week 12) [ Time Frame: Baseline to Week 4 and Week 12 ]
The Tsui rating scale measures severity and duration of head deviation, shoulder elevation and head tremor. This instrument is based on 4 subscores:
- Subscore A: amplitude of rotation, deflection (tilt) and ante- / retrocollis (range: 0-9 points)
- Subscore B: duration of movement (values 1 or 2)
- Subscore C: severity and duration of shoulder elevation (range: 0-3 points)
- Subscore D: severity and duration of tremor (range: 0-4 points).
A higher score for each subscale represents severe CD symptoms. The total score was calculated as follows: total score = subscores (A x B) + C + D. The total score ranges between 0 and 25 points. A high total score represents severe CD.
The mean changes in the subscores A to D of the Tsui rating scale (patient in the sitting position) between baseline (Week 0 visit) and the Week 4 and Week 12 visits are presented.
- Change in the Craniocervical Dystonia Questionnaire (CDQ-24) Total Score and Subscores Between Visit 1 (Week 0) and Visit 2 (Week 4) and Visit 3 (Week 12) [ Time Frame: Baseline to Week 4 and Week 12 ]
The CDQ-24 is a disease-specific quality of life (QoL) instrument and was assessed at Visits 1 to 3. It consists of 24 items investigating problems in daily living skills related to CD.
This instrument is based on 5 subscales: Stigma, Emotional well-being, Pain, Activities of daily living (ADL), Social/family life to which a number of the 24 items are assigned. There are five possible answers to each item representing increasing severity of impairment (scores 0 to 4). The total scores ranged from 0 to 96 (best to worst QoL). In order to obtain scores of the individual subscales, the total score of each subscale (sum of the individual item scores) was transformed linearly to a 0 to 100 scale (best to worst QoL).
The mean changes in the CDQ-24 total score between baseline (Week 0 visit) and the Week 4 and Week 12 visits are presented.
- Changes in the Items of the Patient Diary Based on Day-to-day Function and Activities, Pain and Duration of Pain Between Visit 1 (Week 0) and Visit 2 (Week 4) and Visit 3 (Week 12) [ Time Frame: Baseline to Week 4 and Week 12 ]
The weekly recorded patient diary consists of the three items: Day-to-Day Capacities and Activities, Pain and Duration of Pain. Each item was rated by the patient on an 11-point scale ranging from 0 = no problems at all to 10 = most severe problems (the actual wording is adapted to each item in question).
The mean changes between the baseline (Week 0 visit) and the Week 4 and Week 12 visits are presented.
- Categorical Changes in the Items of the Patient Diary Based on Day-to-day Function and Activities, Pain and Duration of Pain Between Visit 1 (Week 0) and Visit 2 (Week 4) and Visit 3 (Week 12) [ Time Frame: Baseline to Week 4 and Week 12 ]
The weekly recorded patient diary consists of the three items: Day-to-Day Capacities and Activities, Pain and Duration of Pain. Each item was rated by the patient on an 11-point scale ranging from 0 = no problems at all to 10 = most severe problems (the actual wording is adapted to each item in question).
The following categorical changes between the baseline (Week 0 visit) and the Week 4 and Week 12 visits are presented: Improvement, No change and Deterioration.
- Number of Patients Without Pain and/or With a Reduction in Pain Based on a Global Assessment of Pain by the Investigator and by the Patient at Visit 2 (Week 4) and Visit 3 (Week 12) [ Time Frame: Week 4 visit and Week 12 visit ]
Global pain was assessed at Visit 2 (Week 4) and Visit 3 (Week 12); investigators and patients assessed change in global pain according to the following response categories:
- = no pain (anymore)
- = less pain
- = no change
- = more pain
The numbers of patients falling under each of these categories as assessed by the investigator and patient at Weeks 4 and 12 are presented.
- Global Assessment of Efficacy by the Investigator and by the Patient at Visit 2 (Week 4) and Visit 3 (Week 12) [ Time Frame: Week 4 and Week 12 ]
At Visit 2 (Week 4) and Visit 3 (Week 12) investigators and patients assessed global efficacy of injection of 500 U Dysport® according to the following response categories:
- = very good
- = good
- = moderate
- = insufficient
The numbers of patients falling under each of these categories as assessed by the investigator and patient at Weeks 4 and 12 are presented.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- De novo patients with cervical dystonia
- Outpatient
- Patients to be of age 18 years or older
- Written informed consent to participate in the study
Exclusion Criteria:
- Pre-treatment of cervical dystonia with botulinum toxin
- Pre-treatment with botulinum toxin for any indication other than cervical dystonia within the past 12 months
- Pure retro- or antecollis
- Neurological or other diseases which may affect head and neck motor function or neuromuscular transmission, e.g. polyneuropathy with pareses, myasthenia, myopathy, motor neurone diseases, Bekhterev's disease
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00447772
Show 106 study locations
| Study Director: | Ipsen Medical Director | Ipsen |
| Responsible Party: | Ipsen |
| ClinicalTrials.gov Identifier: | NCT00447772 |
| Other Study ID Numbers: |
A-94-52120-098 2004-002086-20 ( EudraCT Number ) |
| First Posted: | March 15, 2007 Key Record Dates |
| Results First Posted: | July 30, 2018 |
| Last Update Posted: | November 22, 2019 |
| Last Verified: | November 2019 |
|
Dysport, Cervical Dystonia |
|
Dystonia Dystonic Disorders Torticollis Dyskinesias Neurologic Manifestations Nervous System Diseases Movement Disorders Central Nervous System Diseases Botulinum Toxins Botulinum Toxins, Type A |
abobotulinumtoxinA Acetylcholine Release Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Cholinergic Agents Neurotransmitter Agents Physiological Effects of Drugs Neuromuscular Agents Peripheral Nervous System Agents |